Literature DB >> 9444933

In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients.

C H Geisler1, P Philip, B E Christensen, K Hou-Jensen, N T Pedersen, O M Jensen, K Thorling, E Andersen, H S Birgens, A Drivsholm, J Ellegaard, J K Larsen, T Plesner, P Brown, P K Andersen, M M Hansen.   

Abstract

Of 560 consecutive, newly diagnosed untreated patients with B CLL submitted for chromosome study, G-banded karyotypes could be obtained in 480 cases (86%). Of these, 345 (72%) had normal karyotypes and 135 (28%) had clonal chromosome abnormalities: trisomy 12 (+12) was found in 40 cases, 20 as +12 alone (+12single), 20 as +12 with additional abnormalities (+12complex). Other frequent findings included abnormalities of 14q, chromosome 17, 13q and 6q. The immunophenotype was typical for CLL in 358 patients (CD5+, Slg(weak), mainly FMC7-) and atypical for CLL in 122 patients (25%) (CD5-, or Slg(strong) or FMC7+). Chromosome abnormalities were found significantly more often in patients with atypical (48%) than in patients with typical CLL phenotype (22%) (P < 0.00005). Also +12complex, 14q+, del6q, and abnormalities of chromosome 17 were significantly more frequent in patients with atypical CLL phenotype, whereas +12single was found equally often in patients with typical and atypical CLL phenotype. The cytomorphology of most of the +12 patients was that of classical CLL irrespective of phenotype. In univariate survival analysis the following cytogenetic findings were significantly correlated to a poor prognosis: chromosome 17 abnormalities, 14q+, an abnormal karyotype, +12complex, more than one cytogenetic event, and the relative number of abnormal mitoses. In multivariate survival analysis chromosome 17 abnormalities were the only cytogenetic findings with independent prognostic value irrespective of immunophenotype. We conclude that in patients with typical CLL immunophenotype, chromosome abnormalities are somewhat less frequent at the time of diagnosis than hitherto believed. +12single is compatible with classical CLL, and has no prognostic influence whereas chromosome 17 abnormalities signify a poor prognosis. In patients with an atypical CLL immunophenotype, chromosome abnormalities including +12complex, 14q+, del 6q and chromosome 17 are found in about 50% of the patients, and in particular chromosome 17 abnormalities suggest a poor prognosis.

Entities:  

Mesh:

Year:  1997        PMID: 9444933     DOI: 10.1016/s0145-2126(97)00095-7

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

1.  Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Authors:  Natarajan Muthusamy; Heather Breidenbach; Leslie Andritsos; Joseph Flynn; Jeffrey Jones; Asha Ramanunni; Xiaokui Mo; David Jarjoura; John C Byrd; Nyla A Heerema
Journal:  Cancer Genet       Date:  2011-02

2.  Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.

Authors:  Kevin J Freise; Aksana K Jones; Doerthe Eckert; Sven Mensing; Shekman L Wong; Rod A Humerickhouse; Walid M Awni; Ahmed Hamed Salem
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

3.  Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.

Authors:  Paolo Strati; Michael J Keating; Susan M O'Brien; Alessandra Ferrajoli; Jan Burger; Stefan Faderl; Francesco Paolo Tambaro; Nitin Jain; William G Wierda
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

4.  Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization.

Authors:  Sunita R Setlur; Chunhwa Ihm; Joelle Tchinda; Soheil Shams; Lillian Werner; Eun Kyung Cho; Christina Thompson; Kimberly Phillips; Laura Z Rassenti; Thomas J Kipps; Donna Neuberg; Arnold S Freedman; Charles Lee; Jennifer R Brown
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

Review 5.  What is the best frontline therapy for patients with CLL and 17p deletion?

Authors:  Xavier C Badoux; Michael J Keating; William G Wierda
Journal:  Curr Hematol Malig Rep       Date:  2011-03       Impact factor: 3.952

6.  Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study.

Authors:  Nyla A Heerema; John C Byrd; Paola S Dal Cin; Marie L Dell' Aquila; Prasad R K Koduru; Ayala Aviram; Stephanie A Smoley; Laura Z Rassenti; Andrew W Greaves; Jennifer R Brown; Kanti R Rai; Thomas J Kipps; Neil E Kay; Daniel L Van Dyke
Journal:  Cancer Genet Cytogenet       Date:  2010-12

7.  Interphase fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia.

Authors:  Wei Xu; Jian-Yong Li; Jin-Lan Pan; Hai-Rong Qiu; Yun-Feng Shen; Li Li; Ya-Fang Wu; Yong-Quan Xue
Journal:  Int J Hematol       Date:  2007-06       Impact factor: 2.490

8.  Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome).

Authors:  Sílvia Beà; Armando López-Guillermo; Maria Ribas; Xavier Puig; Magda Pinyol; Ana Carrió; Lurdes Zamora; Francesc Soler; Francesc Bosch; Stephan Stilgenbauer; Dolors Colomer; Rosa Miró; Emili Montserrat; Elias Campo
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

9.  De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Authors:  Constantine S Tam; Tait D Shanafelt; William G Wierda; Lynne V Abruzzo; Daniel L Van Dyke; Susan O'Brien; Alessandra Ferrajoli; Susan A Lerner; Alice Lynn; Neil E Kay; Michael J Keating
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

10.  Consistent numerical chromosome aberrations in thecofibromas of the ovary.

Authors:  Francesca Micci; Lisbeth Haugom; Vera M Abeler; Claes G Tropé; Håvard E Danielsen; Sverre Heim
Journal:  Virchows Arch       Date:  2008-03       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.